Who Owns Pro Medicus Company?

Pro Medicus Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Truly Controls Pro Medicus?

Understanding the ownership structure of a company is paramount for investors and strategists alike. Pro Medicus, a leader in medical imaging technology, has experienced significant growth, but who exactly steers this Australian powerhouse? Unraveling the Pro Medicus SWOT Analysis reveals the intricate web of stakeholders that have shaped its trajectory since its ASX listing in 2000.

This deep dive into Pro Medicus ownership will explore the evolution of its company structure. We'll examine the influence of major shareholders, the roles of Pro Medicus executives, and the impact of its board of directors on strategic decisions. From its humble beginnings to its current market capitalization, understanding "Who owns Pro Medicus" is key to grasping its future potential and navigating the complexities of the healthcare technology market.

The story of Pro Medicus began in 1983, co-founded by Dr. Sam Hupert and Anthony Hall. This marked the genesis of a company that would become a significant player in the medical technology sector. Understanding the early ownership structure is crucial to grasping the company's trajectory and the alignment of its leaders with shareholder interests.

Dr. Sam Hupert, a Monash University Medical School graduate, transitioned from general practice in late 1984 to dedicate himself full-time to managing the Group. He later became the Chief Executive Officer and Managing Director in October 2010. Anthony Hall, with his background in science, has been the principal architect of the core software systems. He serves as the Technology Director and Executive Director.

The initial ownership structure of Pro Medicus highlights the founders' commitment. Both Dr. Sam Hupert and Anthony Hall held a substantial 25% ownership stake each. This setup ensured that the key executives' interests were closely aligned with those of the shareholders, fostering a strong foundation for the company's growth.

Founders

Dr. Sam Hupert and Anthony Hall co-founded Pro Medicus in 1983.

Initial Ownership

Each founder, Sam Hupert and Anthony Hall, held a 25% stake at the company's inception.

Key Executives

Dr. Sam Hupert serves as CEO and Managing Director, while Anthony Hall is the Technology Director and Executive Director.

Early Focus

The company initially concentrated on secure email and digital systems for medical professionals in Australia.

Early 1990s

Pro Medicus secured one of Australia's first internet domain names.

Alignment of Interests

The significant ownership by the founders ensured that their goals were aligned with those of the Pro Medicus shareholders.

Pro Medicus Ownership Structure and Early Days

The early Pro Medicus ownership structure, with its equal stakes held by the founders, set the stage for the company's future. This structure underscored a shared vision and commitment to the company's success. This ownership model, coupled with the company's early focus on secure digital systems, laid the groundwork for its evolution into a leading medical imaging IT provider. For a deeper understanding of the company's financial model and revenue streams, consider reading about the Revenue Streams & Business Model of Pro Medicus.

• Pro Medicus was founded in 1983.
• The founders, Sam Hupert and Anthony Hall, each held a 25% stake.
• The company's early focus was on secure digital systems for medical professionals.
• This ownership structure helped align the interests of the founders with those of the shareholders.

Pro Medicus SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The evolution of Pro Medicus's ownership structure reflects its significant growth and increasing presence in the market. Initially listed on the Australian Securities Exchange (ASX) on October 10, 2000, with a market capitalization of $142.00 million, the company has experienced substantial expansion. As of June 13, 2025, its market capitalization had surged to A$28.26 billion, demonstrating a compound annual growth rate of 23.91%. The inclusion of Pro Medicus in the ASX 200 on August 1, 2019, further solidified its position and attracted a broader investor base.

The ownership structure of Pro Medicus has evolved over time, with key shifts in shareholder composition. The company's journey, from its initial public offering to its current status, highlights its ability to attract a diverse range of investors, including individual insiders and institutional investors. These changes underscore the company's increasing visibility and attractiveness in the market, as detailed in an article about the Growth Strategy of Pro Medicus.

As of February 5, 2025, individual insiders remain the largest stockholders, holding approximately 49% of the company. Sam Hupert, the CEO, holds a 23.1% stake (24,137,660 shares), and Anthony Hall, the Technology Director and Executive Director, holds a similar 23.1% stake (24,109,000 shares). Institutional investors also hold a significant stake, with The Vanguard Group, Inc. (2.92%) and BlackRock, Inc. (1.91%) among the major shareholders. The general public owns 37% of the company.

Pro Medicus Ownership Overview

Pro Medicus's ownership structure is a mix of individual insiders, institutional investors, and the general public.

• Sam Hupert, CEO, and Anthony Hall, Technology Director, are the largest individual shareholders.
• Institutional investors like The Vanguard Group and BlackRock hold significant stakes.
• The company's market capitalization has grown substantially since its IPO in 2000.
• The inclusion in the ASX 200 increased visibility and investor interest.

Pro Medicus PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current board of directors for Pro Medicus includes both executive and non-executive members. Dr. Sam Aaron Hupert serves as the Managing Director and Chief Executive Officer, while Anthony Barry Hall is the Executive Director and Technology Director. Peter Terence Kempen holds the position of Non-Executive Chairman. The independent non-executive directors are Anthony James Glenning, Dr. Leigh Bernard Farrell, Deena Robyn Shiff, and Alice Williams. Alice Williams is also the Chair of the Audit and Risk Committee and a member of the People and Culture Committee. Deena Shiff chairs the People & Culture committee and is on the Audit and Risk committee. Leigh Farrell also serves on both the People & Culture and Audit and Risk committees.

This structure ensures a mix of operational expertise and independent oversight, contributing to the Pro Medicus company structure and governance. The board's composition is designed to facilitate effective decision-making and strategic guidance, aligning with best practices in corporate governance. The presence of independent directors is crucial for maintaining objectivity and protecting shareholder interests.

Pro Medicus operates under a one-share-one-vote system. As of December 2024, the co-founders, Dr. Sam Hupert and Anthony Hall, held a combined ownership of approximately 46%, giving them substantial influence over the company. This significant ownership stake is a key factor in understanding Pro Medicus ownership and the dynamics of Pro Medicus shareholders. The company's adherence to the ASX Corporate Governance Principles & Recommendations (4th Edition) further underscores its commitment to sound governance practices. For more information on the company's history and ownership, you can refer to this article about Pro Medicus.

Key Takeaways on Pro Medicus Ownership and Governance

Understanding the board of directors and their roles is crucial for investors.

• The board includes both executive and non-executive directors, ensuring a balance of expertise and oversight.
• The co-founders' significant ownership provides them with considerable influence.
• The company follows the ASX Corporate Governance Principles & Recommendations.
• Regular board performance reviews are conducted to ensure effectiveness.

Pro Medicus Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

In recent years, the ownership structure of Pro Medicus has seen notable shifts. In December 2024, co-founders Dr. Sam Hupert and Anthony Hall each sold 1 million shares, totaling 2 million shares, for a combined value of $513.5 million. This strategic move, representing less than 4% of their individual holdings, was aimed at introducing new shareholders and increasing the company's free float, as mentioned by the company's chairman. Despite this, they continue to be the two largest Pro Medicus shareholders, collectively holding 46% of the company's shares.

The company's financial performance has also influenced ownership trends. Pro Medicus announced interim results in February 2025, highlighting significant contract wins, including deals with Trinity Health, Lurie Children's Hospital, and Duly Health and Care, amounting to a minimum of $365 million over 7-10 year agreements. Further contract renewals with Mercy Health in the USA ($98 million, 8 years) and an Australian radiology practice ($32 million, 5 years) bolstered the company's financial position. For FY2024, revenue increased by 29.3% to $161.5 million, with net profit up 36.5% to $82.8 million, and a 27.9% increase in cash at bank, reaching $155.4 million. These strong financials have likely attracted institutional investors, reflecting a positive outlook from analysts.

Industry trends indicate an increase in institutional ownership, which is common for growing companies listed on major indices. The co-founders' recent share sales have slightly diluted their ownership, but they maintain significant control and have no immediate plans for further sales. Considering the company's strong performance and consistent contract wins, the future appears positive, although the valuation remains high, with a price-to-earnings ratio of approximately 245.9 as of the latest data. For more information, you can read a Brief History of Pro Medicus.

Ownership Changes

Co-founders sold shares in December 2024, but remain the largest shareholders. This action aimed to increase the free float and provide opportunities for new investors.

Financial Performance

Strong revenue and profit growth in FY2024, with significant contract wins. The company's cash reserves also saw a substantial increase.

Institutional Interest

Increased institutional ownership indicates a positive view from analysts. The company's strong performance attracts investors.

Valuation

Despite positive trends, the company's valuation remains high. The price-to-earnings ratio is approximately 245.9.

Pro Medicus Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs